Sitagliptin vs Conjugated Estrogens: side-by-side comparison
Sitagliptin (DPP-4 inhibitor) and Conjugated Estrogens (Hormone replacement therapy (estrogen mixture)) belong to different therapeutic classes and are rarely substitutes for each other. The comparison is useful when a single patient is weighing both options for adjacent or overlapping needs.
| Property | Sitagliptin | Conjugated Estrogens |
|---|---|---|
| Therapeutic class | DPP-4 inhibitor | Hormone replacement therapy (estrogen mixture) |
| CAS | 486460-32-6 | 12126-59-9 |
| ATC | A10BH01 | G03CA57 |
| Molecular weight | 407.31 g/mol | 265-272 g/mol (mixture) |
| Brands with this active ingredient | 1 | 1 |
What they share
Sitagliptin and Conjugated Estrogens share the common regulatory framework for prescription active ingredients, bioequivalence standards for generics, and pharmacist oversight. Beyond that, points in common are limited.
Key differences
Sitagliptin acts by a different mechanism than Conjugated Estrogens, with indications that barely overlap. Comparing the two is useful when a clinician has mentioned both in the same context or the patient wants to understand why one was prescribed instead of the other.
Mechanisms compared
Sitagliptin: Sitagliptin reversibly inhibits DPP-4, the serine protease responsible for rapid degradation of glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Conjugated Estrogens: Conjugated estrogens act on estrogen receptors throughout the body, restoring estrogen signalling lost after menopause.
Indications compared
Sitagliptin: Sitagliptin is approved in adults with type 2 diabetes mellitus, alone or in combination with other antidiabetic agents, to improve glycaemic control. Conjugated Estrogens: Conjugated estrogens are approved for moderate to severe vasomotor symptoms of menopause, vulvovaginal atrophy due to menopause, osteoporosis prevention in postmenopausal women at significant risk, and primary ovarian fa…
Safety profile
Sitagliptin: Sitagliptin is generally well tolerated. Conjugated Estrogens: Common adverse effects include nausea, breast tenderness, fluid retention, headache and breakthrough bleeding.
Frequently asked questions
Is Sitagliptin better than Conjugated Estrogens? ▾
Sitagliptin and Conjugated Estrogens are not "better or worse" — they treat different things. The sensible question is which fits your specific need.
Can Sitagliptin and Conjugated Estrogens be combined? ▾
Whether they can be combined depends on the indications and the interaction profile of each. If both are in a single prescription, the prescriber has weighed it; in self-medication they should never be combined.
Do they have the same side-effect profile? ▾
No — they belong to different classes and have distinct side-effect profiles. Each has its own prescribing information.
Products with Sitagliptin
Products with Conjugated Estrogens
The information on this website is provided for reference and educational purposes only. It does not replace consultation with a qualified healthcare professional.